ADX68692

This series of follicle stimulating hormone receptor (FSHR) negative allosteric modulators (NAM) has potential for the treatment of endometriosis, benign prostatic hyperplasia (BPH) and hormone resistant prostate cancer (HRPC).

Back to pipeline